LEO Pharma A/S, a global leader in medical dermatology, announced a major regulatory win in China today. China’s National Medical Products Administration (NMPA) approved Anzupgo® (delgocitinib) cream as a chronic hand eczema treatment. The approval covers adult patients with moderate to severe chronic hand eczema (CHE). It applies to those for whom topical corticosteroids are inadequate or inappropriate.
Moreover, the decision expands access to Anzupgo for patients in China. It also gives adults with moderate to severe CHE a new treatment option. Notably, the approval reflects LEO Pharma’s commitment to improving care in an important market.
“The approval of Anzupgo in China is an important milestone for LEO Pharma and for patients living with moderate to severe chronic hand eczema,” said Frederik Kier, Executive Vice President, International Operations, LEO Pharma. “China is an important market for LEO Pharma, and this approval reflects our continued commitment to supporting skin health in China and bringing innovative treatment options to those who need them most.”
Furthermore, LEO Pharma strengthens its presence in a large and evolving healthcare market. The company points to the sheer number of patients in China. As a result, it builds a strong foundation for offering this treatment to adults with moderate to severe disease.
Understanding the Burden of Chronic Hand Eczema
Chronic hand eczema is a fluctuating disease. Itch and pain define the condition. Patients may also develop erythema, scaling, lichenification, hyperkeratosis, vesicles, edema and fissures on the hands and wrists.
Additionally, CHE places a heavy psychological and functional burden on patients. It affects quality of life and daily functioning. Approximately 70% of individuals living with severe CHE report problems performing everyday activities. They also report disruption in daily life due to the disease.
“People living with chronic hand eczema can experience a significant burden in their daily lives, Currently, there are no treatments specifically indicated for chronic hand eczema in China, creating a clear need for new treatment options in China,” said Byron Yin, General Manager, LEO Pharma China. “The approval of Anzupgo is an important step forward for patients and healthcare professionals, and we are proud to bring this innovation to China as part of our ongoing commitment to improving care for people living with skin diseases.”
Clinical Evidence Behind the Anzupgo Approval
Strong trial data backs the NMPA decision. DELTA China, a phase 3 trial, evaluated the efficacy, safety and pharmacokinetics of Anzupgo. Researchers tested twice-daily applications in Chinese patients with moderate to severe CHE.
During the double-blind treatment period, Anzupgo met the primary endpoint. It showed a statistically significant improvement in CHE severity after 16 weeks of treatment compared with cream vehicles. In addition, the broader delgocitinib clinical program supports the approval. That program includes DELTA 1, DELTA 2, DELTA 3 and DELTA Force.
“The impact of chronic hand eczema goes beyond the skin. It can affect patients’ daily lives, careers and psychological well-being, yet these effects are often overlooked. Many patients face the burden of the disease on their own and continue searching for solutions as the disease flares repeatedly, said Professor Zhang Jianzhong of Peking University People’s Hospital, lead investigator of the DELTA China trial. “We hope to raise awareness of the challenges patients face and promote a better understanding of chronic hand eczema and its appropriate management. We are pleased that delgocitinib cream has now been approved, offering a new treatment option and additional possibilities for improving patients’ lives.”
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com